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TObjectives: The knowledge of chamber-specific gene expression in human atrial and
ventricular myocardium is essential for the understanding of myocardial function
and the basis for the identification of putative therapeutic targets in the treatment of
cardiac arrhythmia and heart failure. In this study the gene expression pattern of
human left atrial and ventricular myocardium was analyzed.
Methods: Global mRNA expression patterns with high-density oligonucleotide
arrays between left atrial and left ventricular myocardium of 6 patients with heart
failure undergoing heart transplantation were compared. Clustering of microarray
data confirmed chamber-specific gene expression profiles. Genes similarly ex-
pressed in all patients were further analyzed, and data were confirmed by means of
real-time polymerase chain reaction and Western blot analysis.
Results: Of 22,215 genes examined, 7115 transcripts were found to be expressed in
all 12 human myocardial samples. One hundred twenty-five genes were differen-
tially expressed between left atrial and left ventricular specimens in all patients
examined. Novel genes preferentially expressed in human atria were identified.
Interestingly, several potassium channels of subfamily K are more highly expressed
in atria than in ventricles. Members of the potassium inwardly rectifying channel of
subfamily J were found to be more highly expressed in human ventricular myocar-
dium. Finally, chronic atrial fibrillation was associated with reduced atrial expres-
sion of the potassium channel TWIK-1, suggesting potential contribution of the
corresponding current to electrical remodeling.
Conclusions: Human atria and ventricles show specific gene expression profiles.
Our data provide the basis of a comprehensive understanding of chamber-specific
gene expression in diseased human hearts and will support the identification of
therapeutic targets in the treatment of arrhythmia and heart failure.
T he functional difference between atrial and ventricular myocardium couldlead to chamber-specific gene expression. Markers of the atrial myocardium(eg, atrial natriuretic peptide)1 and ventricular myocardium (eg, ventricular
myosin light chain 1)2 have been established. However, a comprehensive knowl-
edge of chamber-specific gene expression in the human heart is essential for the
understanding of myocardial function and the basis for the identification of putative
novel drug targets in the specific treatment of cardiac arrhythmia, such as atrial
fibrillation (AF) and heart failure.3
AF is the most frequent sustained arrhythmia, especially in the elderly and
postoperatively as a common complication of cardiac surgery, and has been asso-
ciated with an increased incidence of other complications and increased hospital
length of stay. Most antiarrhythmic drugs are ion channel blockers.4 However, those
tested in a large clinical trial did not reduce mortality. In contrast, their proarrhyth-
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structural heart disease. In this context the identification of
atrium-specific or at least atrium-enriched expression of
genes is a first step in understanding the molecular basis of
AF and identifying new drug targets for AF.
Recently, the Human Genome Project supported the
development of microarrays containing most of the cur-
rently known well-annotated genes of the entire genome,
allowing the identification of differentially expressed genes.
Therefore, we used high-density oligonucleotide arrays
(Affymetrix HG-U133A) to compare the expression of
more than 22,000 transcripts between the left atrial and left
ventricular myocardium of 6 patients undergoing heart
transplantation. We determined the number of genes ex-
pressed in the human heart, found chamber-specific gene
expression pattern, and identified putative new drug targets
in the treatment of arrhythmias and heart failure.
Methods
Patients
Left atrial and ventricular specimens were obtained from 6 male
patients of the Halle Cardiac Transplant Program undergoing
orthotopic cardiac transplantation. After explantation, hearts were
immediately dissected into segments from the left atrial or left
ventricular free lateral wall appearing to consist of myocardium
and avoiding regions with scar tissue and excessive fat or connec-
tive tissue and snap-frozen in liquid nitrogen. The patients were
57 3.2 years old. The hemodynamic data were obtained from the
date at which the last echocardiographic determination of the
ejection fraction (20.5%  2.3%) before transplantation was per-
formed (mean arterial pressure, 78.8  4.9 mm Hg; pulmonary
capillary wedge pressure, 19.8 2.4 mm Hg; cardiac index, 2.5
0.1 L · min1 · m2). The patients had end-stage heart failure
(New York Heart Association functional class IV; 3 with ischemic
cardiomyopathy and 3 with dilated cardiomyopathy) and were
treated with angiotensin-converting enzyme inhibitors, angiotensin
II receptor type 1 (AT1) antagonists, -blockers, nitric oxide
donors, heart glycosides, lipid-lowering drugs, and diuretics.
Right atrial appendages were obtained from 8 patients with
sinus rhythm (SR) and 5 patients with chronic AF (6 months)
undergoing cardiac surgery for coronary artery bypass grafting.
The 2 groups of patients did not differ in terms of sex, age, body
mass index, hypertension, diabetes, hyperlipidemia, or concomi-
tant therapy with angiotensin-converting enzyme inhibitors, AT1
blockers, lipid-lowering drugs, -blockers, diuretics, nitrates, or
glycosides. The study was approved by the local ethics committee.
Each patient provided written informed consent. The investigation
conforms to the principles outlined in the Declaration of Helsinki
(1997).
Gene Array Analysis
RNA and protein isolation. Left atrial and ventricular speci-
mens of patients were dissected immediately after explantation,
snap-frozen, and stored in liquid nitrogen until RNA or protein
preparation. Total RNA from myocardial tissue was isolated with
the RNeasy total RNA isolation system (Qiagen). Protein from
1384 The Journal of Thoracic and Cardiovascular Surgery ● Junatrial and ventricular specimens was isolated by means of mechan-
ical homogenization (Ultraturrax, Janke and Kunkel) in phosphate-
buffered saline containing 1% (vol/vol) Triton X-100 and Com-
plete protease inhibitor cocktail (Roche Diagnostics), followed by
centrifugation to remove insoluble material (30 minutes, 14,000
rpm, 4°C). The protein concentration was determined with the
BCA protein assay reagent (Pierce).
Array hybridization. First- and second-strand cDNA synthesis
was carried out with 10 g of total RNA according to the
Affymetrix Expression Analysis Technical Manual with the High
Yield RNA Transcript Labelling Kit (Enzo). The obtained cRNA
was purified with RNeasy Mini columns (Qiagen) concentrated by
means of ethanol precipitation and quantified by means of UV
spectrophotometry. Yield and size distribution of the labeled tran-
scripts were determined on a Bioanalyzer (Agilent). Each Af-
fymetrix HG-U133A array was hybridized overnight at 45°C with
15 g of labeled and fragmented cRNA. After hybridization, the
gene chips were automatically washed and stained with streptavi-
din-phycoerythrin by using a fluidic station (Affymetrix). The
arrays were analyzed with a Genechip System (Agilent).
Microarray analysis. Affymetrix Microarray Suite software
version 5.0 (MAS 5.0) was used to analyze the relative abundance
of each gene on the basis of the intensity of the signal from each
probe set. A global scaling approach was used to normalize signal
intensities. A target signal value of 500 was used for all arrays. The
MAS 5.0 data files were then transferred into a database and
analyzed with Microsoft Excel and GeneSpring 6.0 software (Sil-
icon genetics). The detection algorithm of MAS 5.0 software was
used to obtain a comprehensive overview of how many transcripts
can be detected in each individual sample. We used significance
levels of P  .04 (present) and P  .06 (absent) to define the
cutoff points of P values for detection calls. MAS 5.0 software
allows a comparative analysis of 2 or more microarray datasets.
Only genes considered to be differentially expressed (increase or
decrease) between atrial and ventricular specimens of the same
donor were further analyzed. Instead of calculating the fold change
by analyzing raw signal intensities, we used the signal log ratio
(SLR) generated by MAS 5.0 software, allowing a more sensitive
detection of smaller changes in gene expression, and calculated the
fold change as follows: FC  2SLR.
Validation with real-time polymerase chain reaction. The
differential expression of genes identified by using oligonucleotide
arrays was confirmed by means of real-time polymerase chain
reaction (PCR) with the TaqMan protocol by using an ABI Prism
7700 sequence detection instrument, as described previously.5
Because the calculated expression level between different samples
was independent of the housekeeping gene used, we decided to
normalize all mRNA expression data to ribosomal protein L32.
The resulting expression shows the mean of 3 independent exper-
iments and is presented in arbitrary units.
Western blot analysis. Western blot analysis was performed
by using 10 g of protein per sample, 4% to 12% NUPAGE
polyacrylamide gels (Invitrogen), and polyvinylidene difluoride
membranes. Expression of TASK-1 protein was determined by
using anti-human TASK-1 antibody (Sigma), the ECL system
(Amersham), and AIDA software (Raytest, Isotopenmessgeraete
GmbH).
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PStatistical analysis. Values are presented as means  SD.
Statistical analysis was performed with the SigmaStat statistical
software (SPSS Inc).
Results
Chamber-specific Gene Expression in the Human
Heart
The Affymetrix HG-U133A microarray allows, in prin-
ciple, the simultaneous quantification of expression of
22,215 mRNA species. To determine the number of tran-
TABLE 1. Genes more than 2-fold higher expressed in atri
Gene
Sarcolipin
Myosin, light polypeptide 4, alkali; atrial, embryonic
A kinase (PRKA) anchor protein 3
Potassium channel, subfamily K, member 1 (TWIK-1)
Myosin, heavy polypeptide 6, cardiac muscle
Titin immunoglobulin domain protein (myotilin)
Signal transducer and activator of transcription 4
Nuclear receptor subfamily 2, group F, member 1 (COUP-TF 1)
NADP-dependent retinol dehydrogenase-reductase
Natriuretic peptide precursor B
Desmocollin 1
Potassium voltage-gated channel, shaker-related subfamily, mem
Secreted frizzled-related protein 1
Phospholipase A2, group IIA (platelets, synovial fluid)
Keratin 18
dickkopf homolog 3 (Xenopus laevis)
Natriuretic peptide precursor A
Guanine nucleotide-binding protein (G protein), 5
Potassium channel, subfamily K, member 3 (TASK-1)
H factor 1 (complement)
Upregulated by BCG-CWS
Phosphodiesterase 8B
Cartilage oligomeric matrix protein
Complement component 3
Sparc/osteonectin, cwcv and kazal-like domains proteoglycan (te
Phospholipase C, 1 (phosphoinositide-specific)
Chromosome 1 open reading frame 15
Corin
Myosin light chain 2a
Transmembrane 6 superfamily member 1
FK506 binding protein 11, 19 kd
Visinin-like 1
Angiotensin II receptor, type 1
H factor (complement)-like 2
NY-REN-58 antigen
Similar to neuralin 1
Duffy blood group
Transgelin
Potassium intermediate/small conductance calcium-activated, KC
Endothelin receptor type A
*Atrial versus ventricular myocardium.scripts expressed in the failing human myocardium, we
The Journal of Thoracicquantified the mRNAs expressed in all 12 left atrial or
left ventricular biopsy specimens. The detection algo-
rithm of Affymetrix MAS software allows a potential
vote for each single array experiment in determining
whether the measured transcript is detected (present) or
not detected (absent). By using this algorithm, 7115
transcripts were found to be expressed in all 12 human
myocardial samples. However, the number of mRNA
species detected at least once in a single human myocar-
yocardium compared with ventricular myocardium
Fold change*
(mean), n  6 Accession no. P value
9.62 NM_003063 .0001
9.19 M36172 .0001
8.67 NM_006422 .0124
6.73 U90065 .0001
5.59 D00943 .0001
5.34 NM_006790 .0022
5.22 NM_003151 .0002
4.87 AI951185 .0001
4.24 NM_005771 .0008
4.24 NM_002521 .0001
4.24 NM_004948 .0001
4.09 NM_002234 .0001
4.05 NM_003012 .0001
3.95 NM_000300 .0108
3.78 NM_000224 .0042
3.73 NM_013253 .0001
3.69 M30262 .0006
3.52 NM_006578 .0001
3.36 NM_002246 .0001
3.32 X04697 .0030
3.10 NM_022154 .0001
2.96 AK023913 .0001
2.86 NM_000095 .0018
2.70 NM_000064 .0135
n) 2.70 AF231124 .0002
2.70 AL049593 .0001
2.64 AF288395 .0001
2.58 NM_006587 .0012
2.49 NM_021223 .0001
2.43 NM_023003 .0001
2.41 NM_016594 .0001
2.41 NM_003385 .0002
2.41 NM_004835 .0004
2.32 X56210 .0085
2.30 NM_016122 .0001
2.22 AL049176 .0171
2.07 NM_002036 .0108
2.05 NM_003186 .0005
2.02 NM_021614 .0006
2.02 NM_001957 .0009al m
ber 5
stica
NN2dial biopsy specimen was much higher (12,522). This last
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CSPnumber also includes genes expressed in atrial myocar-
dium but with an expression level of less than the detec-
tion limit in the ventricle and vice versa.
Interestingly, the number of expressed genes detected in
human atrial specimens is consistently higher than that
detected in the ventricular specimen from the same donor.
In atrial myocardium an average of 46.2%  1.2% of the
22,215 mRNA species on the Affymetrix HG-U133A array
could be detected, whereas the average percentage for ven-
tricular specimens was only 42.2%  1.4% (P  .05). To
perform a comprehensive analysis of all genes differentially
expressed between human atrial and ventricular myocar-
dium, we used the change call algorithm of Affymetrix
software for subsequent gene selection. The change call
algorithm is totally independent from the absent-present
detection algorithm and allows a reproducible decision as to
whether a transcript level is increased or decreased to a
minor or major degree or not changed by comparing 2
different array experiments. Thus, by using the change call
algorithm, it is possible to identify changes in the transcript
level between the atrium and ventricle of the same donor,
even if the expression is too low for a present call on one
TABLE 2. Genes more than 2-fold higher expressed in ven
Gene
Delta-like 1 homolog (Drosophila)
Myosin, light polypeptide 3, alkali; ventricular, skeletal, slow
HSKM-B protein
Ankyrin repeat domain 2 (stretch-responsive muscle)
KIAA1733 protein
Four-and-a-half LIM domain–containing protein 2
Carboxypeptidase, vitellogenic-like
Protein tyrosine phosphatase, nonreceptor type 3
Myosin, light polypeptide 2, regulatory, cardiac, slow
Gamma-aminobutyric acid (GABA) A receptor,  4
Dihydropyrimidinase-like 4
Hypothetical protein FLJ20156
Hypothetical protein FLJ14054
Potassium inwardly-rectifying channel, subfamily J, member 2
Hypothetical protein FLJ32389
Ribosomal protein L3-like
NDRG family member 4
Hairy/enhancer-of-split related with YRPW motif 2
IMAGE:3862861, mRNA, complete cds
Isocitrate dehydrogenase 2 (NADP), mitochondrial
Likely ortholog of mouse limb-bud and heart gene
Hypothetical protein FLJ21901
Phospholipase C-like 1
Lipoprotein lipase
LRP16 protein
Phosphofructokinase, muscle
*Atrial versus ventricular myocardium.array. Only genes consistently differentially expressed be-
1386 The Journal of Thoracic and Cardiovascular Surgery ● Juntween duplicate arrays were further analyzed. One hundred
twenty-five genes were identified to be differentially ex-
pressed between left atrial and ventricular specimens in all
6 patients examined. Of those, Table 1 shows 40 genes with
a more than 2.0-fold higher expression in the left atrium
compared with that seen in the left ventricle, whereas Table
2 shows 26 genes with a more than 2.0-fold change in the
left ventricle compared with that seen in the left atrium.
Hierarchical Clustering of Array Experiments
Hierarchical clustering of all array experiments was carried
out to further confirm the chamber-specific gene pattern. In
the agglomerative approach for hierarchical clustering, the
chamber-specific expression profile of each patient is joined
with the profiles of the other patients to form groups,
resulting in a hierarchical tree.6 For this hierarchical clus-
tering, we selected only those 7115 mRNA species detected
in all 12 myocardial samples. By using this approach, the
software allowed a correct classification into atrial and
ventricular specimens. However, when comparing only
atrial or ventricular specimens, no correlation of similarity
in the gene expression pattern with cause (eg, differences
lar myocardium compared with atrial myocardium
Fold change*
(mean), n  6 Accession no. P value
0.07 U15979 .0002
0.10 NM_000258 .0001
0.10 AF070592 .0025
0.16 NM_020349 .0017
0.19 AW054711 .0001
0.20 NM_001450 .0006
0.27 NM_031311 .0001
0.28 NM_002829 .0001
0.31 AF020768 .0001
0.33 NM_000809 .0001
0.35 NM_006426 .0349
0.36 NM_017691 .0069
0.37 NM_024563 .0001
0.39 AF153820 .0001
0.41 AL551046 .0001
0.41 NM_005061 .0001
0.41 AV724216 .0004
0.43 NM_012259 .0062
0.44 BG332462 .0001
0.44 U52144 .0001
0.45 NM_030915 .0001
0.45 NM_024622 .0000
0.46 NM_006226 .0002
0.46 NM_000237 .0001
0.47 NM_014067 .0001
0.49 U24183 .0001tricubetween hearts from patients with ischemic or dilated car-
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PFigure 1. Real-time PCR (TaqMan) verification of selected genes consistently differentially expressed between
atrial and ventricular specimens from all 6 patients. Solid bars represent normalized mRNA expression in the left
atrium; open bars represent the expression level in the left ventricles ( SD calculated from 3 independent
measurements).
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hierarchical clustering of microarray data.
The chamber-specific expression pattern was not caused
by a different content of vascular tissue in the specimen
selected because the expression of marker genes for endo-
thelial cells (eg, von Willebrand factor and endothelial
cell-specific Tie2 receptor tyrosine kinase) or vascular
smooth muscle cells (eg, smooth muscle–specific myosin
heavy chain 1 and smooth muscle isoform of myosin reg-
ulatory light chain 2) did not differ between left atrial or
ventricular samples in microarray data. Furthermore, mark-
ers of neuronal tissue (eg, neuronal specific transcription
factor DAT1 and neuronal amiloride–sensitive cation chan-
nels 1 and 2) and markers of increased infiltration of in-
flammatory cells (eg, macrophage antigen  polypeptide
CD11b) were not differentially expressed in specific myo-
cardial samples.
Specific Genes with a Preferential Atrial or
Ventricular Expression
The correct classification of all specimens into left atria and
ventricles was furthermore examined by means of real-time
PCR analysis of the atrial marker gene atrial natriuretic
peptide and the ventricular marker gene ventricular myosin
light chain 1. Chamber-specific marker gene expression
confirmed the anatomic and histologic classification. Cham-
ber-specific expression of several putative drug targets in
the treatment of arrhythmia or heart failure was confirmed
by means of real-time PCR. We found a preferred atrial
expression of putative or established drug targets (eg, phos-
phodiesterase 8B, endothelin receptor type A, and AT1;
Figure 1). Several potassium channels, including TWIK-1
1388 The Journal of Thoracic and Cardiovascular Surgery ● Jun(KCNK1), TASK-1 (KCNK3), Kv1.5 (KCNA5), and SK2
(KCNN2), are more highly expressed in the atrium than in
the ventricle, whereas a higher ventricular expression of
potassium channel Kir2.1 (KCNJ2) was observed (Figure
1). For TASK-1, a commercially available antibody allowed
the confirmation of differential expression also on the pro-
tein level.
Potassium Channel Expression in Patients with
Chronic AF
Next, we studied whether expression of the potassium chan-
nels Kv1.5, TASK-1, Kir2.1, and TWIK-1 is modified in the
atria of patients with chronic AF. We found no change in
Kv1.5, TASK-1, and Kir2.1 expression between the SR and
AF groups. However, TWIK-1 mRNA was less abundant in
the AF than in the SR group (Figure 2).
Discussion
In this study we compared the chamber-specific expression
pattern in failing human hearts. The number of more than
22,000 mRNA species that can be detected with the Af-
fymetrix HG-U133A array allows a comprehensive view of
the number of genes expressed in human atrial and ventric-
ular myocardium. We found more than 7000 mRNA species
to be expressed in all 12 human myocardial samples. This
number highlights the number of active genes in the human
heart but might be due to the detection limit of the array
technology, even an underestimation.7 Furthermore, indi-
vidual genetic or clinical differences between patients might
reduce the number of genes consistently expressed in all
atrial or ventricular specimens. For the specific gene expres-
Figure 2. Expression of potassium channels
in atrial myocardium of patients with SR and
AF. The mRNA expression of the potassium
channels Kv1.5, TASK-1, Kir2.1, and TWIK-1
was quantified by means of real-time PCR
(TaqMan) in the atrial myocardium of 13 pa-
tients with coronary artery disease undergo-
ing coronary artery bypass grafting surgery
and with SR or chronic AF. Bars represent
normalized mRNA expression ( SD; *P< .05
vs SR).sion profile, the anatomic and functional differences be-
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These differences might include chamber-specific hemody-
namic parameters and tissue composition. However, we did
not find a different expression of markers of endothelial,
vascular smooth muscle, neuronal, or inflammatory cells
between left atrial and left ventricular specimens.
We could confirm a chamber-specific expression pattern
for several genes that have recently been identified to be
expressed in murine hearts in a similar manner (eg, pre-
ferred atrial expression of sarcolipin,8 dickkopf homolog 3
[Xenopus laevis], and myosin light chain 2a9) and a pre-
ferred ventricular expression of four-and-a-half LIM do-
main– containing protein 2.10 The chamber-specific expres-
sion pattern of “up-regulated by BCG-CWS,” dickkopf
homolog 3 (X laevis), and ankyrin repeat domain 2 found by
us is in agreement with recent studies using RZPD filters
preferentially directed to identify genes expressed in human
congenitally malformed hearts.11 The 2-fold higher atrial
expression of endothelin receptor A is in agreement with
our previous findings in the atrial and ventricular myocar-
dium of patients with heart failure.12,13
Recently, in an excellent study Ruel and colleagues14
described the changes in gene expression profile in right
atrial myocardium and skeletal muscle before and approx-
imately 1 hour after cardiopulmonary bypass and cardiople-
gic arrest. In this study we compared the gene expression
pattern between the left atria and left ventricles of hearts
explanted from patients undergoing heart transplantation
and identified a different set of genes. This further supports
the specificity of our findings.
Regarding putative new drug targets for the treatment of
AF, we found a higher expression of several potassium
channels in atrial myocardium compared with that seen in
ventricular myocardium. This is of special interest because
it has long been known that blockade of cardiac potassium
channels and the resulting prolongation of repolarization
and refractoriness is the mode of action of class III antiar-
rhythmic drugs, which are currently used for the treatment
of AF. Potassium channels encoded by HERG underlie the
delayed rectifier current (IKr), a sensitive target for most
class III antiarrhythmic drugs, including methanesulfon-
amides, such as sotalol. However, their clinical use is lim-
ited by their side effects in the form of ventricular tachy-
cardia because prolongation of ventricular repolarization
seems to be invariably associated with proarrhythmia. Not
much is known about the differences in the regional expres-
sion of the corresponding molecular targets for these drugs.
In general, blockade of a cardiac current that is exclusively
present in the atria is highly desirable because it is expected
to be devoid of ventricular proarrhythmic effects.15
In the human heart the ultrarapid delayed rectifier potas-
sium current (IKur) and its molecular correlate, the cardiac
Kv1.5 channel, were identified in atrial but not in ventric-
The Journal of Thoracicular tissue by means of electrophysiologic experiments.
Therefore, our finding that the Kv1.5 channel has a pre-
ferred atrial mRNA expression supports the idea that this
potassium channel is an attractive target in the search for
novel and safer atrial antiarrhythmic drugs.16 In accordance
with our findings and with electrophysiologic experiments,
an atrium-enriched expression of Kv1.5 mRNA was previ-
ously described.17 Moreover, expression of Kv1.5 channel
subunits and current density were lower in the atria of
patients with chronic AF compared with those of patients
with SR.18 Here the mRNA levels of Kv1.5 did not differ
between patients with SR and those with AF. Therefore, the
reduction of IKur might occur only in a subpopulation of
patients with chronic AF.19
We furthermore identified 2-pore domain potassium
channels to be preferentially expressed in atrial myocar-
dium. For TASK-1, a preferred atrial expression has thus far
only been demonstrated in rats.20 In patients with chronic
AF, TASK-1 mRNA levels were similar to those seen in
patients with SR, which contrasts with the reduced abun-
dance of several K currents during AF.19 Because contri-
bution of TASK-1 to action potential repolarization should
be larger in AF than in SR, blocking this channel might
prolong action potential duration in these patients and rep-
resents a new therapeutic option for AF treatment.
Interestingly, the mRNA levels of the inward rectifier K
channel TWIK-1 were significantly lower in patients with
AF than in patients with SR, suggesting potential contribu-
tion of the corresponding current to electrical remodeling.
Regarding ventricular-enriched genes, microarray data re-
vealed that the potassium channel Kir2.1 (KCNJ2) is more
abundantly expressed in ventricular myocardium compared
with in atrial myocardium in all patients. Because of the
limited availability of corresponding tissues, we could analyze
Kir2.1 expression in the atrial myocardium of patients with AF
only. Atrial Kir2.1 mRNA expression was unchanged. These
findings contrast with recent results showing that current den-
sity of the inward rectifier K current (IK1) and mRNA levels
of one of its channel subunits (Kir2.1) were 2-fold higher in
right atrial tissue of patients with AF.21
We found a predominant expression of AT1 in left atrial
myocardium. The role of the AT1 receptor in AF is not
clear. Although initial studies showed a downregulation of
atrial AT1 mRNA and protein expression in patients with
AF,22 an increased AT1 protein expression was recently
described in the left atrial tissue of patients with AF.23 In
contrast, the expression of endothelin receptor type A is not
altered in patients with AF.24
In conclusion, a specific gene expression profile was
found in human atrial and ventricular myocardium. Our data
provide the basis of a comprehensive understanding of
chamber-specific gene expression in the human heart and
and Cardiovascular Surgery ● Volume 129, Number 6 1389
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treatment of cardiac arrhythmia and heart failure.
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